Furthermore, several other therapeutic molecules and pathways with potent antifibrotic effects were described in the past decade, such as metformin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), pentraxin 3 (PTX3), protein kinase Cζ and δ, angiotensin/AT2, maresin 1, and aspirin-triggered lipoxin A4 (ATLA/FPR2), which bring new perspectives to the development of an appropriate pharmacological treatment for pulmonary fibrosis (53–60). This evidence concerns the gene FPR2 and pulmonary fibrosis.